Satoko Minakawa

Dr. Satoko Minakawa

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
EMEiko Makita
Eiko Makita
YMYasushi Matsuzaki
Yasushi Matsuzaki
TFTomohisa Fukui
Tomohisa Fukui
AMAkinobu Matsui
Akinobu Matsui
SMSatoko Minakawa
Satoko Minakawa
DSDaisuke Sawamura
Daisuke Sawamura

1 December 2013 in Journal of Dermatological Science
Verified
Journal Article
Closed access
SMSatoko Minakawa
Satoko Minakawa
HNHajime Nakano
Hajime Nakano
KNKoji Nakajima
Koji Nakajima
YMYasushi Matsuzaki
Yasushi Matsuzaki
NTNoriko Takiyoshi
Noriko Takiyoshi
DSDaisuke Sawamura
Daisuke Sawamura

10 December 2017 in Analytical Sciences
Verified
Journal Article
Closed access
PDF file
Kouichi NakagawaKouichi Nakagawa
Kouichi Nakagawa
SMSatoko Minakawa
Satoko Minakawa
DSDaisuke Sawamura
Daisuke Sawamura
HHHideyuki Hara
Hideyuki Hara
Continuous wave electron paramagnetic resonance (CW EPR) and X-band (9 GHz) EPR imaging (EPRI) were used to nondestructively investigate the possible differentiation between malignant melanoma (MM) and nevus pigmentosus (NP) melanin radicals in paraffin-embedded specimens. The EPR spectra of both samples were analyzed using linewidth, spectral pattern, and X-band EPRI. The CW-EPR spectra of the MM showed an additional signal overlap. Eumelanin- and pheomelanin-related radicals were observed in the MM specimens. The EPR results revealed that the peak-to-peak linewidths (ΔHpp) of paraffin-embedded MM and NP samples were 0.65 ± 0.01 and 0.69 ± 0.01 mT, respectively. The g-value was 2.005 for both samples. Moreover, the two-dimensional (2D) EPRI of the MM showed different signal intensities at the different tumor stages, unlike the NP, which displayed fewer variations in signal intensity. Thus, the present results suggest that EPR and 2D EPRI can be useful for characterization of the two melanin radicals in the MM and for determination of their size and concentration.

1 May 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
NSNorihiro Saito
Norihiro Saito
MIMasamichi Itoga
Masamichi Itoga
SMSatoko Minakawa
Satoko Minakawa
HKHiroyuki Kayaba
Hiroyuki Kayaba
Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are often used to treat outpatients with psychogenic somatoform symptoms but prove ineffective in some cases. The metabolite 3-hydroxybutyrate (3HB) is currently attracting attention as a marker of the severity of depression. We investigated whether serum 3HB levels in patients with psychogenic somatoform symptoms can predict the effectiveness of sertraline and venlafaxine. Patients and Methods: Physical and psychiatric problems were assessed in 132 outpatients, and symptomatic response and serum 3HB concentrations were examined before and after treatment with sertraline (50 mg/day) or venlafaxine (75 mg/day). Results: In 30.3% of patients with psychogenic symptoms, serum 3HB was above the upper limit of normal (< 80 μmol/L). According to multiple logistic regression analysis, only episodes of suicidal ideation showed a significant positive association with elevated 3HB (odds ratio 10.2; 95% confidence interval (CI) 2.46– 42.2). The sensitivity of 3HB for the effectiveness of sertraline or venlafaxine for psychosomatic symptoms was 44.6%, but specificity was 93.9%. Hierarchical multiple logistic regression analysis identified 3HB as a better predictor of the effectiveness of medication (odds ratio 10.0; 95% CI, 2.49– 40.3) than episodes of suicidal ideation. Conclusion: The present findings suggest that high serum 3HB levels in patients with psychogenic somatoform symptoms may be associated with suicidal ideation and the effectiveness of sertraline and venlafaxine at low to intermediate doses. The 3HB level may be a good predictor of the effectiveness of medication. Examination of serum 3HB levels may lead to earlier and more appropriate administration of sertraline and venlafaxine.

12 March 2009 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SMSatoko Minakawa
Satoko Minakawa
HNH. Nakano
H. Nakano
HTH. Takeda
H. Takeda
HMH. Mizukami
H. Mizukami
SYS. Yagihashi
S. Yagihashi
DSD. Sawamura
D. Sawamura

2 September 2009 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SMSatoko Minakawa
Satoko Minakawa
HTH. Takeda
H. Takeda
HNH. Nakano
H. Nakano
CTC. Tono
C. Tono
YTY. Takahashi
Y. Takahashi
DSD. Sawamura
D. Sawamura